On February 10, 2026 iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, reported financial results for the second quarter ended Dec. 31, 2025, and provided a corporate update on its progress.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We have significantly advanced our preclinical pipeline programs – IBIO-610, our activin E antibody, and IBIO-600, our myostatin antibody – towards the start of human clinical trials by initiating CMC development and toxicology studies," said Martin Brenner, Ph.D., DVM, Chief Executive Officer and Chief Scientific Officer of iBio. "Additionally, we recently completed a $26 million private placement financing with a highly respected biotech investor, strengthening our resources for pipeline progress and taking us one step closer to fulfilling our mission of reaching patients in need of an accessible, transformative therapy for obesity. The positive news positions us well to execute on our planned milestones and corporate priorities throughout 2026 and 2027."

Second Fiscal Quarter 2026 & Recent Corporate Updates:

Closed a $26 million private placement financing led by Frazier Life Sciences, announced on January 9th. The net proceeds from the raise are intended for the advancement of key preclinical cardiometabolic programs, including IBIO-610, IBIO-600, and the myostatin and activin A bispecific programs, as well as general corporate purposes. With this funding the Company’s cash runway now extends into third quarter of fiscal year 2028.
Presented new non-human primate (NHP) data on IBIO-610, a potentially first-in-class Activin E antibody candidate, showing it has a predicted human half-life of up to 100 days. Such data supports potential dosing as infrequently as twice per year.
Advanced preclinical pipeline across multiple programs:
IBIO-610 NHP, CMC, and toxicology studies are ongoing and remain on track to support the commencement of first human clinical trials in early calendar year 2027.
IBIO-600 is completing toxicology studies and is on track to enter Phase 1a clinical trials in the first half of calendar year 2026.
Preclinical development efforts also continued for the Company’s bispecific myostatin × activin A program and amylin candidates.
Delivered an oral presentation at the 2nd Annual Innovation in Obesity Therapeutics Summit on December 4, 2025, titled "Next-Generation Obesity Therapeutics: Long-Acting Antibodies for Improved Quality of Weight Loss."
Delivered an oral presentation at PepTalk, The Protein Science and Production Week event, on January 21, 2026, titled "Membrane Protein Targets Reengineered for Soluble Expression."
Delivered an oral presentation at the Keystone Symposia on Obesity Therapeutics on January 29, 2026, titled "Neutralization of Activin E Promotes Fat-Selective Weight Loss and Prevents Weight Regain in Preclinical Models of Obesity."

Financial Results:

No revenue was recognized for the three months ending December 31, 2025. Revenue of $0.2 million was recognized for the three months ending December 31, 2024.

Research and Development ("R&D") expenses for the three months ending December 31, 2025, and December 31, 2024, were $4.3 million and $1.9 million, respectively, an increase of approximately $2.4 million. The increase in R&D expenses is mainly due to increased spending on consultants and outside services supporting the Company’s R&D efforts, including conducting the NHP studies and CMC activities, and an increase in personnel costs as a result of advancing research activities for the Company’s IBIO-600 and IBIO-610 programs and other preclinical pipeline assets. The increase was partially offset by decreased spending on consumable supplies.

General and Administrative expenses for the three months ending December 31, 2025, and December 31, 2024, were approximately $5.2 million and $2.7 million, respectively, an increase of $2.5 million. The increase is primarily attributable to the impairment of the Company’s indefinite lived intangible asset IBIO-101.

iBio held cash, cash equivalents and investments in debt securities of $52.7 million as of December 31, 2025. In addition, in January 2026, the Company received net proceeds of approximately $24.4 million from the PIPE financing extending the Company’s cash runway into third quarter of fiscal year 2028.

(Press release, iBioPharma, FEB 10, 2026, View Source [SID1234662566])